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Abstract  
Introduction: Type 1 insulin-like growth factor receptor (IGF-IR) is deregulated in solid 
tumors. Cixutumumab, a monoclonal antibody that inhibits IGF-IR activity, was investigated in 
combination with pemetrexed/cisplatin in the front-line setting. 
Methods: In this open-label, Phase II study, patients with Stage IV nonsquamous non-small cell 
lung cancer (NSq-NSCLC) and a performance status of 0–1 were randomized (1:1) to receive 20 
mg/kg cixutumumab, 500 mg/m2 pemetrexed, and 75 mg/m2 cisplatin (cixutumumab; n = 87) or 
pemetrexed and cisplatin (control; n = 85). Eligible patients received pemetrexed-based 
maintenance therapy with (cixutumumab arm) or without (control arm) cixutumumab. The 
primary endpoint was progression-free survival (PFS). Secondary endpoints assessed overall 
survival (OS), objective response rate (ORR), and safety. Survival was analyzed by Kaplan-
Meier method and Cox’s proportional hazard model. Exploratory correlative analyses were also 
performed. 
Results: The mean age of the intent-to-treat (ITT) population (n = 172) was 59 years (range, 32–
83). Median PFS was 5.45 months with cixutumumab vs. 5.22 months with control (hazard ratio 
[HR] 1.15; 95% confidence interval [CI], 0.81–1.61; P = 0.44). Median OS was 11.33 months 
with cixutumumab vs. 10.38 months with control (HR 0.93, 95% CI, 0.64–1.36). ORR did not 
differ between treatments (P = 0.338). Grade 3/4 hyperglycemia occurred at a higher rate with 
cixutumumab than control (9.4% vs. 1.2%). One death possibly related to cixutumumab 
occurred.  
Conclusions: Efficacy was not improved in NSq-NSCLC patients when cixutumumab was 
added to pemetrexed/cisplatin. Combination therapy was well tolerated and no new safety 
concerns were reported. 
 
Keywords: cixutumumab, IMC-A12, first-line therapy, pemetrexed, NSCLC 
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INTRODUCTION 
Nonsquamous non-small cell lung cancer (NSq-NSCLC) accounts for the majority of 
patients with NSCLC and often presents as advanced/metastatic disease at diagnosis. On 
average, the median survival time of untreated patients with advanced NSq-NSCLC is 
approximately 4 months after diagnosis. However, for patients with good performance status, 
first-line platinum-based chemotherapy improves both survival and quality of life.1 
Platinum-based doublets have shown no significant differences in objective response rate 
(ORR), progression-free survival (PFS), or overall survival (OS).2,3 Other clinical factors not 
considered with traditional chemotherapy, such as histologic subtype, may also influence clinical 
outcome. Patients with advanced NSCLC with non-squamous histology benefited more from 
pemetrexed/cisplatin than cisplatin/gemcitabine in terms of OS (hazard ratio [HR] 0.81; P = 
0.005), while PFS was similar between arms.4 This evidence provided a rationale for the current 
patient population in addition to the need for effective treatments for patients with NSq-NSCLC 
who may not have oncogenic alterations. 
It is clear that type 1 insulin-like growth factor receptor (IGF-IR) has significant 
implications in NSCLC. Cixutumumab (IMC-A12; Eli Lilly and Company, Indianapolis, IN, 
USA), a human IgG monoclonal antibody, blocks IGF-IR activity and inhibits tumor survival 
and growth in numerous solid tumor types, including lung cancer, and in human tumor xenograft 
models in vivo, both alone5 and combined with chemotherapy.6 However, the clinical benefit of 
adding cixutumumab to chemotherapy in patients with advanced NSq-NSCLC is unknown.   
This open-label, multicenter, randomized Phase II study assessed whether adding 
cixutumumab to pemetrexed/cisplatin was superior to pemetrexed/cisplatin as first-line therapy 
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in patients with advanced NSq-NSCLC. Biomarkers potentially predictive of cixutumumab 
efficacy were also evaluated.  
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MATERIALS AND METHODS 
Patients and Study Design    
An overview of the study design and treatment plan has been fully described in Figure 1. 
Prior to enrollment, an institutional review board reviewed and approved the study protocol. 
Patients who met the eligibility criteria (Figure 1) were enrolled in the study. Intravenous (IV) 
cixutumumab infusions were administered first, followed by an IV pemetrexed infusion 1 hour 
later and an IV cisplatin infusion 30 minutes after pemetrexed. All patients received vitamin B12, 
folic acid supplementation, and prophylactic dexamethasone. Patients continued maintenance 
therapy until disease progression, unacceptable toxicity, noncompliance, or withdrawal of 
consent.  
 
Statistical Analysis 
Patients (n = 156) were planned for the superiority test of comparing PFS, assuming a 
median PFS of 5.3 months (control arm) and an expected median PFS of 7.16 months 
(cixutumumab arm; HR cixutumumab/control = 0.74). With a power of 80% (1-sided 
significance level of 20%; 1:1 ratio) to detect an HR of 0.74, 125 events were required for 
analysis.  
The HR of cixutumumab/control for PFS was determined using the Cox’s proportional 
hazard model. PFS, OS, and time-to-progressive disease (TTPD) were estimated using the 
Kaplan-Meier method and differences assessed by log-rank test. The ORRs were compared using 
Fisher’s exact test. Radiographic imaging assessed the percentage change in tumor size from 
baseline to the end of cycle 2; comparisons were analyzed using a t-test. Safety was assessed 
using Common Terminology Criteria for Adverse Events version 4.0. 
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An exploratory correlative research and a pharmacokinetics (PK) analysis of 
cixutumumab were also performed (see Supplemental Digital Content text for analysis methods). 
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RESULTS 
Clinical Efficacy 
 
 A total of 172 patients were randomized (cixutumumab, n = 87; control, n = 85). Patients 
discontinued in the cixutumumab and control arms, respectively, due to progressive disease 
(40% and 37%), adverse events (AEs; 20% and 15%), and death (11% for both arms). Baseline 
patient and disease characteristics (Table 1) of the ITT population were similar between arms.  
 The median PFS was 5.45 months with cixutumumab and 5.22 months with control (HR 
1.15; 95% confidence interval [CI], 0.81–1.61), with no statistically significant difference 
between arms (Figure 2A). Similarly, no statistically significant difference in OS between arms 
was observed, but the median OS (Figure 2B) was numerically higher with cixutumumab than 
control (11.33 months vs. 10.38 months; HR 0.93; 95% CI, 0.64–1.36). 
 The ORR was 37.9% and 30.6% with cixutumumab and control, respectively (P = 
0.338). Best tumor responses were similar between arms (Table 2), with more patients 
experiencing a partial response (37.9% vs. 30.6%) or progressive disease (16.1% vs. 12.9%) with 
cixutumumab than control. There was a similar percentage of clinical benefit responders between 
arms (P = 0.511). 
 The median TTPD was 6.05 months with both cixutumumab (95% CI, 5.32–7.79) and 
control (95% CI, 4.93–7.89). In addition, although the mean percent change from baseline in 
tumor size was greater with cixutumumab (mean ± standard deviation, -23.88 ± 18.86) versus 
control (-16.04 ± 26.14), the difference was not statistically significant. 
 
Safety 
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The safety analyses included 166 patients (cixutumumab, n = 85; control, n = 81). As 
shown in Table 3, Grade 3 or 4 treatment-emergent AEs possibly related to treatment occurred 
more frequently with cixutumumab (56.5%) than control (43.2%). As expected, hyperglycemia 
(all grades) occurred at a higher rate with cixutumumab (41.2%) than control (7.4%). 
Dehydration (all grades), a known effect of cisplatin treatment, was also more frequently 
reported with cixutumumab (17.7%) than control (6.2%). 
Discontinuation rates due to serious AEs (SAEs) possibly related to any study drug were 
similar between arms (cixutumumab, 7.1%; control, 8.6%). Three patients experienced SAEs 
possibly related to cixutumumab that led to discontinuation (1 SAE each of myocardial 
infarction, pancytopenia, and sepsis). Four patients in each arm died and deaths were considered 
possibly related to any study drug; 1 death (due to sepsis) was possibly cixutumumab related. 
 
Pharmacokinetics  
PK analysis of cixutumumab was performed using available serum concentration-time 
data (n = 83; Supplemental text). Overall, serum concentrations of cixutumumab increased after 
each cixutumumab infusion and accumulation of cixutumumab was observed (Supplemental 
Figure 1). Cixutumumab clearance was low (0.02 L/hr) and had a long terminal elimination half-
life (8 days; Supplemental Table 1). 
 
Exploratory Correlative Analyses  
Circulating and tumor-specific candidate biomarkers were also evaluated (Supplemental 
text and Supplemental Tables 2-5). No statistically significant interactions were demonstrated; 
however, compared with the control arm, numerically longer PFS, OS, or both PFS and OS were 
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observed in cixutumumab-treated patients with low circulating total IGF-I levels (25th percentile 
cutpoint), TP53 mutations, and high IGF-IR/IR ratio (75th percentile cutpoint) in tumor tissue, 
respectively.    
 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
DISCUSSION 
This phase II study failed to support the hypothesis that adding cixutumumab to 
pemetrexed/cisplatin was superior to pemetrexed/cisplatin alone as first-line therapy in patients 
with advanced, metastatic NSq-NSCLC. No new safety concerns were reported. Similarly, 
studies of cixutumumab combined with other chemotherapies as a first-line therapy in other solid 
tumors have also found little to no benefit from adding cixutumumab.7,8  
 The lack of efficacy observed may be due, at least in part, to the administration sequence 
of IGF-IR inhibitors and chemotherapeutic agents.9 In breast cancer cells, growth inhibition 
improves when chemotherapy (doxorubicin and gemcitabine) is administered before IGF-IR 
inhibition, and an opposite effect with the reverse administration.10,11 Here, cixutumumab was 
administered first followed by pemetrexed/cisplatin, all on the same day.  
The addition of cixutumumab to pemetrexed/cisplatin chemotherapy did not lead to any 
significant increase in toxicity, except for hyperglycemia, which is common among 
cixutumumab patients. Similar safety profiles have been observed when cixutumumab was 
combined with mitotane7 and gemcitabine and erlotinib.12 Dose-limiting toxicities were reported 
when erlotinib and cixutumumab were combined in patients with NSCLC, a finding supported 
when other anti-IGF-IR monoclonal antibodies were unsuccessfully combined with full-dose 
erlotinib in patients with NSCLC.8 
 Clinical biomarkers may also predict clinical outcomes for IGF-IR-directed therapy. 
Since IGF-IR monoclonal antibodies failed to demonstrate significant clinical benefit in general 
patient populations,13 studies are exploring the relationship between circulating biomarkers and 
clinical outcome. Elevated IGF binding protein-1 correlated with improved PFS (P = 0.009) and 
OS (P = 0.003) in patients with advanced hepatocellular carcinoma who were administered 
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cixutumumab.14 In addition, low IGF-I baseline levels were associated with significantly shorter 
OS with a figitumumab combination therapy regimen versus control (P = 0.01), whereas patients 
with high HbA1c baseline levels had a lower median OS with combined figitumumab therapy 
versus control (P = 0.05).15 Based on our exploratory biomarker analysis, numerically longer 
PFS, OS, or both PFS and OS were recorded in cixutumumab-treated patients with low 
circulating total IGF-I levels, TP53 mutations, and high tumor IGF-IR/IR ratio, respectively. Of 
note, the biomarker analysis was limited due to the small sample size in subgroups that were 
defined by marker class by treatment and a high censoring rate in OS. 
 In summary, cixutumumab added to pemetrexed/cisplatin does not improve clinical 
outcome as measured in PFS in patients with NSq-NSCLC as a first-line therapy. Our findings 
corroborate the work of others and suggest that IGF-IR inhibition is largely ineffective in NSq-
NSCLC patients. However, since none of the IGF-IR clinical studies enriched for a specific 
biomarker population, it is plausible that only select NSq-NSCLC patients benefit from the anti-
IGF-IR antibodies. Predictive potential of the IGF-IR/IR ratio, TP53 mutational status, and total 
IGF-I levels warrants further investigation in clinical trials with biomarker-driven design. 
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Figure Legends 
Figure 1. Study Design. ECOG PS, Eastern Cooperative Oncology Group Performance Status; 
EGFR, epidermal growth factor receptor; IGF-IR, type 1 insulin-like growth factor receptor; 
NSq-NSCLC, nonsquamous non-small cell lung cancer. 
Figure 2. (A) Progression-free and (B) overall survival Kaplan-Meier curves for the 
cixutumumab (red) and control (blue) treatment arms in the ITT population. HR, hazard ratio; 
CI, confidence interval. 
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Table 1. Patient Demographics and Disease Characteristics at Baseline (Intent-to-Treat Population) 
 Cixutumumab Arm 
(n = 87) 
Control Arm 
(n = 85) 
Sex, n (%)   
Male 54 (62.1) 53 (62.4) 
Race, n (%)   
White 81 (97.6) 80 (96.4) 
Non-White 2 (2.4) 3 (3.6) 
Missing 4 (4.6) 2 (2.4) 
Age (years)   
Mean (SD) 59.5 (9.87) 59.3 (9.96) 
Median 59 60 
ECOG Performance Status, n (%)   
0 41 (47.1) 41 (48.2) 
1 46 (52.9) 44 (51.8) 
Basis for Pathological Diagnosis, n (%)   
Histological 74 (85.1) 74 (87.1) 
Cytological 13 (14.9) 11 (12.9) 
Histology at Entry or Initial Diagnosis, n (%)   
Adenocarcinoma 80 (92.0) 75 (88.2) 
Large Cell 1 (1.1) 0 
Other 6 (6.9) 10 (11.8) 
Disease Stage at Initial Diagnosis, n (%)   
IA/IB 2 (2.2) 0 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
 Cixutumumab Arm 
(n = 87) 
Control Arm 
(n = 85) 
IIIA 5 (5.7) 6 (7.1) 
IIIB 2 (2.3) 1 (1.2) 
IV 78 (89.7) 78 (91.8) 
Smoking Status, n (%)   
Never 15 (17.2) 13 (15.3) 
Ever 72 (82.8) 72 (84.7) 
Prior Therapies*, n (%)   
Surgery 13 (14.9) 14 (16.5) 
Radiotherapy 17 (19.5) 22 (25.9) 
Systemic therapy 3 (3.4) 7 (8.2) 
ECOG, Eastern Cooperative Oncology Group; n, number of patients; SD, standard deviation. 
*Patients may have received more than 1 prior therapy. 
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Table 2. Best Overall Tumor Response 
 Cixutumumab Arm 
(n = 87) 
Control Arm 
(n = 85) 
P value 
(Fisher’s exact test) 
Complete response, n 0 0  
Partial response, n 33 26  
% (95% CI) 37.9 (27.7, 48.1) 30.6 (20.8, 40.4)  
Stable disease, n 25 35  
% (95% CI) 28.7 (19.2, 38.2) 41.2 (30.7, 51.6)  
Progressive disease, n 14 11  
% (95% CI) 16.1 (8.4, 23.8) 12.9 (5.8, 20.1)  
Not assessed, n (%) 15 (17.2) 13 (15.3)  
Overall response rate    
CR+PR responders, n 33 26 0.338 
% (95% CI, Exact method) 37.9 (27.7, 49.0) 30.6 (21.0, 41.5)  
Disease control rate    
CR+PR+SD responders, n 58 61 0.511 
% (95% CI, Exact method) 66.7 (55.7, 76.4) 71.8 (61.0, 81.0)  
CI, confidence interval; CR+PR, complete response and partial response; CR+PR+SD, complete response, partial response, and stable disease; n, number of 
patients. 
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Table 3. Treatment-Emergent AEs Possibly Related to Any Treatment Reported in ≥10% of Patients (Safety Population) 
 Cixutumumab Arm 
(n = 85) 
Control Arm 
(n = 81) 
  Grade  Grade 
CTCAE Term All Grades 3 4 5 
All 
Grades 3 4 5 
Patients with ≥1 TEAE 82 (96.5) 39 (45.9) 9 (10.6) 4 (4.7) 72 (88.9) 30 (37.0) 5 (6.2) 4 (4.9) 
Anemia 24 (28.2) 8 (9.4) 0 0 28 (34.6) 8 (9.9) 2 (2.5) 0 
Anorexia 23 (27.1) 6 (7.1) 0 0 22 (27.2) 1 (1.2) 0 0 
Constipation 14 (16.5) 1 (1.2) 0 0 11 (13.6) 0 0 0 
Creatinine increased 8 (9.4) 1 (1.2) 0 0 13 (16.0) 1 (1.2) 0 0 
Dehydration 15 (17.7) 4 (4.7) 1 (1.2) 0 5 (6.2) 0 0 0 
Diarrhea 15 (17.7) 2 (2.4) 0 0 12 (14.8) 2 (2.5) 0 0 
Fatigue 33 (38.8) 7 (8.2) 0 0 33 (40.7) 8 (9.9) 0 0 
Hyperglycemia 35 (41.2) 7 (8.2) 1 (1.2) 0 6 (7.4) 1 (1.2) 0 0 
Mucositis oral 22 (25.9) 3 (3.5) 0 0 10 (12.3) 2 (2.5) 0 0 
Nausea 18 (21.2) 4 (4.7) 0 0 25 (30.9) 1 (1.2) 0 0 
Neutrophil count decreased 25 (29.4) 12 (14.1) 2 (2.4) 2 (2.4) 21 (25.9) 10 (12.3) 3 (3.7) 1 (1.2) 
Platelet count decreased 15 (17.6) 4 (4.7) 3 (3.5) 1 (1.2) 9 (11.1) 1 (1.2) 2 (2.5) 0 
Vomiting 30 (35.3) 7 (8.2) 0 0 24 (29.6) 1 (1.2) 0 0 
Weight loss 10 (11.8) 0 0 0 7 (8.6) 1 (1.2) 0 0 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
White blood cell decreased 11 (12.9) 0 4 (4.7) 0 7 (8.6) 1 (1.2) 1 (1.2) 0 
CTCAE, Common Terminology Criteria for Adverse Events; n, number of patients; TEAE, treatment-emergent adverse event. 
Data are reported as n (%) for the highest grade TEAE per patient. 
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Figure 1. Study Design 
 
 
 
Inclusion Criteria 
• ≥ 18 years of age 
• Histologic or cytologic 
NSq-NSCLC diagnosis 
• ECOG PS 0 or 1 
• Diagnosis of Stage IV 
NSq-NSCLC or 
metastatic, recurrent 
disease 
• Adequate bone marrow 
reserve, renal and hepatic 
function, and fasting 
serum glucose and 
hemoglobin A1c levels 
 
Exclusion Criteria 
• Other cancer diagnoses 
• Previous chemotherapy 
• Treatment with 
pemetrexed or other IGF-
IR/EGFR agents 
• Pregnancy 
• Leptomeningeal disease 
• Diabetes mellitus 
• Other intercurrent 
illnesses/infections 
Randomization  
1:1 
Cixutumumab Arm:  
20 mg/kg cixutumumab 
500 mg/m2 pemetrexed 
75 mg/m2 cisplatin 
Control Arm:  
500 mg/m2 pemetrexed 
75 mg/m2 cisplatin 
INDUCTION 
(every 21 days up to 6 cycles) 
Cixutumumab Arm:  
20 mg/kg cixutumumab 
500 mg/m2 pemetrexed 
Control Arm:  
500 mg/m2 pemetrexed 
MAINTENANCE 
(every 21 days until discontinuation) 
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Figure 2A. Progression-Free Survival 
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Figure 2B. Overall Survival 
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Supplemental Digital Content 
Pharmacokinetic Analysis Methods 
Cixutumumab serum concentration in pharmacokinetic (PK) samples was 
determined using a validated enzyme-linked immunosorbent assay (ELISA) method at 
Pharmaceutical Product Development (PPD; Richmond, VA, USA). The lower limit of 
quantification was 2500 ng/mL, and the upper limit of quantification (ULOQ) was 100 
000 ng/mL. Samples with values above the ULOQ were diluted to yield results within the 
calibrated range. The inter-assay accuracy (% relative error) during validation ranged 
from -7.93% to 3.14%. The inter-assay precision (% relative standard deviation) during 
validation ranged from 8.70% to 23.0%. 
Serial blood samples for PK analysis were collected approximately at pre-dose 
and at 1, 168, 336, and 504 (also referred to as pre-infusion sample for subsequent cycle) 
hours post end of infusion following first through fourth infusions. Additional samples 
were collected approximately 72 hours post end of the first infusion; and at 
approximately 24, 72, 120, and 240 hours post end of the fourth infusion. From the eighth 
infusion onwards, 2 samples (pre- and 1 hour post end of infusion) were collected at 
every fourth infusion.  
PK data were analyzed by non-compartmental analysis using Phoenix WinNonlin 
(Version 6.3).  
 
Pharmacokinetic Analysis 
 PK analysis was performed using available serum concentration-time data (n = 
83). Serum concentrations of cixutumumab increased between the first through fourth 
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infusions and showed accumulation of cixutumumab when administered every 3 weeks 
(Supplemental Figure 1) and geometric mean accumulation ratio calculated using AUC 
was 1.18 (coefficient of variation [CV%], 33%). The geometric means of cixutumumab 
concentrations before the eighth and twelfth infusions were 65.9 µg/mL (CV%, 70%; n = 
17) and 94.6 µg/mL (CV%, 57%; n = 8), respectively. Cixutumumab has low clearance 
(0.02 L/hr) and long terminal elimination half-life (8 days; Supplemental Table 1).  
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Exploratory Correlative Research Methods 
Sample collection was mandatory for these analyses. Pretreatment serum or 
plasma samples were collected to assess circulating levels of insulin, C-peptide, free IGF-
I, total IGF-I, total IGF-II, IGF binding proteins 1-3 (IGFBP-1, IGFBP-2, IGFBP-3) by 
enzyme-linked immunoassay (ELISA; LabCorp, New York, NY, USA). Pretreatment 
formalin-fixed paraffin-embedded tissue samples were subjected to total RNA and 
genomic DNA extraction followed by evaluation of type 1 insulin-like growth factor 
receptor (IGF-IR), insulin receptor A and B isoforms (IRA, IRB), ratio of IGF-IR to total 
IR, IGF-I, IGF-II, IGFBP-3, INSIG2, ERCC1, TYMS, IL10, and ITGB3 mRNA 
expression (Asuragen, Austin, TX, USA) and mutational analysis of TP53 (exons 4-9) 
and KRAS (exon 2) genes using TaqMan qPCR and the SURVEYOR-WAVE Nucleic 
Acid High Sensitivity Fragment Analysis System (Transgenomic, New Haven, CT, 
USA), respectively. All assays were analytically validated and were fit for the intended 
use. The list of TaqMan® gene expression assays (Life Technologies, Grand Island, NY, 
USA) is provided below (Supplemental Table 2). 
Each marker was independently analyzed against efficacy endpoints (progression-
free survival (PFS) and overall survival (OS) using a treatment-dependent interaction 
model. Patients were dichotomized into high- and low-expression subgroups using the 
25th, median, and 75th percentile cutpoints for continuous biomarkers (circulating proteins 
and mRNA-based biomarkers), and into mutation positive and negative (wildtype [WT]) 
subgroups for TP53 and KRAS mutations. Cox regression interaction model included 
dichotomized marker expression class, treatment indicator, interaction between marker 
class and treatment, and additional baseline covariates (age group [<65 vs. ≥65], gender 
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[female vs. male], and smoking status [ever vs. never]). All translational research 
analyses were exploratory and conducted at a 2-sided alpha level of 0.05. No multiplicity 
adjustments were performed across markers and endpoints. 
 
Exploratory Correlative Research 
Of the 172 patients in the intent-to-treat (ITT) population, biomarker analyses 
included 142 (82.6%), 122 (70.9%), and 126 (73.3%) patients with at least 1 evaluable 
assay for immunoassay, gene expression, and mutational analysis data, respectively. 
Baseline demographics were similar between the ITT and biomarker populations; 
however, minor differences in PFS and OS were noted between the ITT populations and 
biomarker populations (data not shown). 
 
Circulating Biomarkers 
Significant interaction effects between dichotomized protein levels and treatment 
were observed for serum total IGF-I and PFS (25th percentile Q1 cutpoint), and plasma 
IGFBP-3 and OS (75th percentile Q3 cutpoint). Patients with low total IGF-I (Q1 cutpoint 
= 103 ug/L) generally had longer PFS in the cixutumumab arm (PFS hazard ratio [HR] 
[95% CI], 0.60 [0.28-1.31], P = 0.204, interaction P = 0.027), while patients with high 
total IGF-I generally had longer PFS and OS in the control arm (PFS HR [95% CI], 1.72 
[1.07–2.77], P = 0.023, interaction P = 0.027; OS HR [95% CI], 1.37 [0.70–2.67], P = 
0.354, interaction P = 0.240). Patients with high IGFBP-3 expression (Q3 cutpoint = 
142.598 nmol/L) had generally longer PFS and OS in the control arm (PFS HR [95% CI], 
2.13 [0.94–4.81], P = 0.073, interaction P = 0.170; OS HR [95% CI], 3.07 [0.92–10.25], 
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P = 0.057, interaction P = 0.045; Supplemental Table 3). No significant interaction 
effects were observed for other circulating proteins and PFS and OS. 
 
 
mRNA-based Biomarkers 
No significant interaction effects were observed for dichotomized mRNA-based 
biomarkers and PFS and OS. Although not significant, patients with high IGF- R/IR ratio 
(Q3 cutpoint = 2.49) generally had longer PFS and OS in the cixutumumab arm (PFS HR 
[95% CI], 0.61 [0.26–1.43], P = 0.249, interaction P = 0.057; OS HR [95% CI], 0.46 
[0.14–1.53], P = 0.189, interaction P = 0.193), while patients with lower ratio generally 
had longer PFS in the control arm (PFS HR [95% CI], 1.57 [0.95–2.61], P = 0.076, 
interaction P = 0.057; Supplemental Table 4). 
 
TP53 and KRAS Mutations 
No significant interaction between TP53 and KRAS mutations and PFS or OS was 
observed. Patients with somatic TP53 mutations generally had longer OS in the 
cixutumumab arm (OS HR [95% CI], 0.68 [0.35–1.32], P = 0.255, interaction P = 0.067), 
while patients that were WT T 53 had longer PFS and OS in the control arm (PFS HR 
[95% CI], 2.11 [1.11–4.02], P = 0.020, interaction P = 0.056; OS HR [95% CI], 1.79 
[0.80–4.02], P = 0.146, interaction P = 0.067; Supplemental Table 5). No apparent 
association between KRAS mutations and cixutumumab efficacy was observed. 
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Supplemental Table 1. Summary of Pharmacokinetic Parameters of Cixutumumab Following Every 3 Weeks of  
Cixutumumab Infusionsa With Cisplatin and Pemetrexed as First-Line Therapy in Patients With Advanced  
Nonsquamous NSCLC 
 
Infusion 
Number PK Summary 
Cmaxb 
(µg/mL) 
tmaxc 
(hr) 
t1/2d 
(days) 
AUCe 
(µg*hr/mL) 
CLf 
(L/hr) 
Vss 
(L) 
First 
nPK 71 71 60 57 57 57 
Geometric Mean 
(CV%) 
481 
(33) 
2.33 
(1.00 – 3.50) 
6.91 
(2.88 - 13.6) 
73200 
(35) 
0.0202 
(30) 
4.27 
(24) 
Fourth 
nPK 31 31 40 27 27 27 
Geometric Mean 
(CV%) 
556 
(17) 
2.13 
(1.00 – 3.00) 
8.48 
(4.19 – 12.7) 
79700 
(30) 
0.0173 
(28) 
4.38 
(17) 
AUC, area under the concentration time curve; Cmax, maximum serum concentration; CL, total body clearance; CV, coefficient of variation;  
hr, hours; n, number of patients; NSCLC, non-small cell lung cancer; nPK, number of pharmacokinetic observations; PK, pharmacokinetic;  
tmax, time of maximum observed drug concentration; t1/2, terminal elimination half-life; VSS, volume of distribution at steady state. 
a Infusion duration varied from 0.42 to 3.08 hours. 
b Concentration at 0 to 2 hours from end of infusion. 
c Median (min-max) are presented for tmax. 
d Geometric mean (min-max) are presented for t1/2. 
e AUC(0-∞), area under the concentration time curve from time 0 to infinity is presented following first infusion and AUC(0-tau), area under the  
concentration time curve during 1 dosing interval (504 hours) is presented following fourth infusion. 
f
 CL is calculated as dose/AUC(0-∞) following first infusion and as dose/AUC(0-tau) following fourth infusion. 
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Supplemental Table 2. Gene Expression Assays 
 
Target TaqMan Probes Number Sequences 
IGF-IR Hs00609566_m1 N/A 
INSR (Total IR) Hs00961554_m1 N/A 
INSR (IR-B) 
IRB (IR-Long) 
custom design.  
cat# AIRR9AF, 
PN4331348 
probe: 5’-TCCCCAGAAAAACCTC-3’, 
F primer: 5’-CCTGCACAACGTGGTTTTCG-3’ 
R primer: 5’-CGGCACCAGTGCCTGAA-3’ 
IGF-I Hs01547656_m1 N/A 
IGF-II Hs01005963_m1  N/A 
IGFBP3 Hs00181211_m1 N/A 
INSIG2 Hs00379223_m1 N/A 
ERCC1 Hs01012158_m1 N/A 
TYMS Hs00426586_m1 N/A 
IL10 Hs00961622_m1 N/A 
ITGB3 Hs01001469_m1 N/A 
ERCC1, excision repair cross-complementation group 1; IGF-I, insulin growth factor 
type I; IGF-II, insulin growth factor type II; IGF-IR, insulin-like growth factor I receptor; 
IGFBP3, insulin growth factor binding protein-3; IL10, interleukin 10; INSIG2, insulin 
induced gene 2; INSR (IR-B), insulin receptor B isoform; INSR (Total IR), total insulin 
receptor; ITGB3, integrin beta-3; N/A, not applicable; TYMS, thymidylate synthase. 
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Supplemental Table 3. Interaction model: Cox regression of PFS and OS for Total IGF-I and IGFBP-3  
 
  
Marker 
  
Sample Size 
  
Parameter 
High Levels Low Levels 
Cixutumumab Control Cixutumumab Control 
Total IGF-I 
(Cutpoint:  
Q1 = 103 
ug/L) 
50, 51, 18, 15 
mPFS (95% CI) 5.3 (3.5–6.0) 7.1 (5.0–8.7) 5.8 (1.5–8.9) 6.5 (2.1–5.6) 
PFS HR (95% CI) 
P value 
1.72 (1.07–2.77) 
P = 0.023 
0.60 (0.28–1.31) 
P = 0.204 
Interaction P value Interaction P = 0.027 
mOS (95% CI) NR (8.3–NR) NR (13.0–NR) 7.5 (2.5–13.0) 5.6 (3.1–6.4) 
OS HR (95% CI) 
P value 
1.37 (0.70–2.67) 
P = 0.354 
0.73 (0.32–1.63) 
P = 0.439 
Interaction P value Interaction P = 0.240 
IGFBP-3 
(Cutpoint:  
Q3 = 142.598 
nmol/L) 
16, 19, 52, 47 
mPFS (95% CI) 5.5 (4.1–6.0) 7.9 (7.1–9.7) 4.8 (2.7–6.7) 4.9 (3.9–6.2) 
PFS HR (95% CI) 
P value 
2.13 (0.94–4.81) 
P = 0.073 
1.10 (0.69–1.74) 
P = 0.693 
Interaction P value Interaction P = 0.170 
mOS (95% CI) 9.6 (5.8–NR) NR (NR–NR) 13.0 (7.5–NR) 8.1 (5.7–NR) 
OS HR (95% CI) 
P value 
3.07 (0.92–10.25) 
P = 0.057 
0.82 (0.46–1.44) 
P = 0.490 
Interaction P value Interaction P = 0.045 
Note: Interaction model: Cox regression of PFS/OS includes marker class, treatment, interaction between marker class and  
treatment, and additional covariates of age group, gender and smoking status. The reported sample sizes represent the number  
of patients with high (total IGF-I or IGFBP-3) expression in the cixutumumab arm, high (total IGF-I or IGFBP-3) expression in  
the control arm, low (total IGF-I or IGFBP-3) expression in the cixutumumab arm, and low (total IGF-I or IGFBP-3) expression  
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in the control arm, respectively. High and low levels were defined as the 75th and 25th percentile cutpoint, respectively. Bolded P value 
indicates statistical significance. 
CI, confidence interval; HR, hazard ratio; IGFBP-3, insulin growth factor binding protein 3; IGF-I, insulin growth factor type I; NR, 
not reported; mOS, median overall survival; mPFS, median progression-free survival; OS, overall survival; PFS, progression-free 
survival; Q1, 1st quartile; Q3, 3rd quartile. 
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Supplemental Table 4. Interaction model: Cox regression of PFS and OS for ratio of IGF-IR to Total IR (INSR)   
 
  
Marker 
  
Sample Size 
  
Parameter 
High Ratio Low Ratio 
Cixutumumab Control Cixutumumab Control 
IGF-IR/IR 
Ratio  
(Cutpoint:  
Q3 = 2.49) 
11, 16, 42, 39 
mPFS (95% CI) 7.0 (3.9–8.9) 2.8 (1.6–6.7) 5.4 (3.1–6.0) 6.2 (4.9–7.9) 
PFS HR (95% CI) 
P value 
0.61 (0.26–1.43) 
P = 0.249 
1.57 (0.95–2.61) 
P = 0.076 
Interaction P value Interaction P = 0.057 
mOS (95% CI) NR (8.7–NR) 6.1 (4.4–NR) 9.4 (7.3–NR) 11.3 (7.6–NR) 
OS HR (95% CI) 
P value 
0.46 (0.14–1.53) 
P = 0.189 
1.10 (0.60–2.03) 
P = 0.750 
Interaction P value Interaction P = 0.193 
Note: Interaction model: Cox regression of PFS/OS includes marker class, treatment, interaction between marker class and  
treatment, and additional covariates of age group, gender and smoking status. The reported sample sizes represent the number  
of patients who had a high expression of IGF-IR/IR ratio in the cixutumumab arm, high expression of IGF-IR/IR ratio in the  
control arm, low expression of IGF-IR/IR ratio in the cixutumumab arm, and low expression of IGF-IR/IR ratio in the control  
arm, respectively. High and low ratios were defined as the 75th and 25th percentile cutpoint, respectively. 
CI, confidence interval; HR, hazard ratio; IGF-IR, insulin-like growth factor I receptor; IR, insulin receptor; mOS, median overall 
survival; mPFS, median progression-free survival; OS, overall survival; PFS, progression-free survival; Q3, 3rd quartile. 
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Supplemental Table 5. Interaction model: Cox regression of PFS and OS for TP53 and KRAS mutations  
 
  
Marker 
  
Sample Size 
  
Parameter 
Mutation Positive WT 
Cixutumumab Control Cixutumumab Control 
TP53 31, 36, 33, 26 
mPFS (95% CI) 5.8 (4.3–7.3) 4.5 (3.9–5.7) 5.8 (2.8–7.4) 7.4 (6.2–10.4) 
PFS HR (95% CI) 
P value 
0.94 (0.56–1.59) 
P = 0.828 
2.11 (1.11–4.02) 
P = 0.020 
Interaction P value Interaction P = 0.056 
mOS (95% CI) 10.6 (8.7–NR) 8.0 (5.9–14.4) 8.9 (7.3–NR) NR (10.4–NR) 
OS HR (95% CI) 
P value 
0.68 (0.35–1.32) 
P = 0.255 
1.79 (0.80–4.02) 
P = 0.146 
Interaction P value Interaction P = 0.067 
KRAS 22, 16, 41, 44 
mPFS (95% CI) 4.8 (2.7–7.3) 4.3 (2.7–6.2) 5.8 (4.8–7.4) 6.0 (4.6–7.5) 
PFS HR (95% CI) 
P value 
0.90 (0.44–1.84) 
P = 0.780 
1.29 (0.79–2.11) 
P = 0.310 
Interaction P value Interaction P = 0.425 
mOS (95% CI) 9.4 (5.8–NR) 10.5 (4.2–NR) 13.0 (8.3–NR) 11.3 (7.4–NR) 
OS HR (95% CI) 
P value 
1.02 (0.44–2.37) 
P = 0.958 
0.95 (0.51–1.77) 
P = 0.869 
Interaction P value Interaction P = 0.889 
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Note: Interaction model: Cox regression of PFS/OS includes mutation status, treatment, interaction between mutation status and 
treatment, and additional covariates of age group, gender and smoking status. The reported sample sizes represent the number of 
patients who are mutation positive (TP53 or KRAS gene) in the cixutumumab arm, mutation positive (TP53 or KRAS gene) in  
the control arm, mutation negative (wild type TP53 or KRAS) in the cixutumumab arm, and mutation negative (wild type TP53  
or KRAS) in the control arm, respectively. Bolded P value indicates statistical significance. 
CI, confidence interval; HR, hazard ratio; KRAS, Kirsten rat sarcoma viral oncogene homolog; mOS, median overall survival; mPFS, 
median progression-free survival;  
NR, not reported; OS, overall survival; PFS, progression-free survival; TP53, tumor protein 53; WT, wild type. 
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Supplemental Figure 1. Mean (+/- standard deviation [SD]) serum concentration-time 
profiles on linear scale (left panel) and semi-logarithmic scale (without SD, right panel) 
of cixutumumab following every 3 weeks of IV infusion of 20 mg/kg cixutumumab over 
1.0 to 1.5 hours with cisplatin and pemetrexed as first-line therapy in patients with 
advanced NSq-NSCLC. Hr, hours. 
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Supplemental Figure 1. Serum Concentration vs. Time Profile of Cixutumumab 
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